About china sxt pharmaceuticals inc - SXTC
China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.
SXTC At a Glance
China Sxt Pharmaceuticals, Inc.
178 Taidong North Road
Taizhou, Jiangsu 225300
| Phone | 86-523-86299087 | Revenue | 1.14M | |
| Industry | Pharmaceuticals: Major | Net Income | -6,205,085.00 | |
| Sector | Health Technology | Employees | 56 | |
| Fiscal Year-end | 03 / 2027 | |||
| View SEC Filings |
SXTC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.003 |
| Price to Book Ratio | 0.054 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 3.684 |
| Enterprise Value to Sales | -22.77 |
| Total Debt to Enterprise Value | -0.043 |
SXTC Efficiency
| Revenue/Employee | 20,322.357 |
| Income Per Employee | -110,805.089 |
| Receivables Turnover | 0.352 |
| Total Asset Turnover | 0.04 |
SXTC Liquidity
| Current Ratio | 7.935 |
| Quick Ratio | 7.255 |
| Cash Ratio | 6.478 |
SXTC Profitability
| Gross Margin | 21.853 |
| Operating Margin | -630.629 |
| Pretax Margin | -545.237 |
| Net Margin | -545.237 |
| Return on Assets | -21.997 |
| Return on Equity | -27.488 |
| Return on Total Capital | -20.128 |
| Return on Invested Capital | -26.945 |
SXTC Capital Structure
| Total Debt to Total Equity | 3.773 |
| Total Debt to Total Capital | 3.636 |
| Total Debt to Total Assets | 3.225 |
| Long-Term Debt to Equity | 2.349 |
| Long-Term Debt to Total Capital | 2.264 |